EIF2AK3 and Miyoshi myopathy: Taken together, we present clear evidence for MK-2206 alone or in combination with rapamycin, a PI3K inhibitor, an inhibitor of the Mek/Erk pathway or dexamethasone to be taken up for clinical investigation in MM patients, and most importantly, to use baseline expression of pAkt and pERK as companion biomarkers in patient selection for clinical trials with this agent.